<DOC>
	<DOC>NCT01726790</DOC>
	<brief_summary>To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection</brief_summary>
	<brief_title>Effect of Intravitreal Bevacizumab on Corneal Endothelium</brief_title>
	<detailed_description>Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.</detailed_description>
	<mesh_term>Corneal Endothelial Cell Loss</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>aged between 20 and 80 years old can come to regular follow up at 6 month signed written consent forms not have corneal scar, or glaucoma history of treatment with laser or antiVEGF therapy in 3 month prior to recruit high risk in cerebrovascular and cardiovascular diseases Pregnancy and breastfeeding can undergo confocal microspopy History of intraocular surgery or ocular trauma during study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>corneal endothelium</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Confoscan</keyword>
</DOC>